Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note published on Tuesday morning,Benzinga reports. Chardan Capital currently has a $55.00 target price on the stock.
A number of other research firms also recently weighed in on SLN. Jefferies Financial Group started coverage on Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price for the company. Morgan Stanley restated an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Monday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $57.20.
Get Our Latest Stock Analysis on Silence Therapeutics
Silence Therapeutics Trading Down 7.4 %
Institutional Investors Weigh In On Silence Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Eventide Asset Management LLC bought a new position in shares of Silence Therapeutics in the third quarter worth about $11,635,000. Parkman Healthcare Partners LLC boosted its position in Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares in the last quarter. Nicholas Investment Partners LP acquired a new stake in Silence Therapeutics in the second quarter valued at approximately $2,859,000. Point72 Asset Management L.P. increased its holdings in shares of Silence Therapeutics by 1,686.6% during the second quarter. Point72 Asset Management L.P. now owns 146,500 shares of the company’s stock worth $2,784,000 after buying an additional 138,300 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after acquiring an additional 268,250 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Where to Find Earnings Call Transcripts
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Why Invest in High-Yield Dividend Stocks?
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Business Services Stocks Investing
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.